The combined NF1, RAF, and RTK alterations from EGFR, PDGFRA, FGFR3, and Multi-RTK subgroups that activate the ERK/MAPK signaling pathway (Figure 1B) accounted for 85% of the glioblastoma IDH-wild-type cases. This evidence concerns the gene EGFR and glioblastoma.